Dr. Assistant Professor

The study included 30 donors and 30 simultaneous recipients who underwent OLT procedure from living donors between 2018 and 2019. The age range of the patients was 19 to 65 years. Participants who had oncological and hematological diseases, coronary or kidney failure, malnutrition, diabetes, traumatic brain injury or cadaveric LT, and who were using psychoactive medicines, having a respiratory system or CNS diseases were excluded from the study. Demographic data of patients, accompanying diseases, ASA classification, main etiology, the recent MELD, and CTP scores were recorded together with laboratory results routinely taken before the operations. During the operations; anesthetic medicines, duration of the operations, anesthesia, prehepatic, anhepatic, post hepatic phases, graft warm ischemia and graft cold ischemia times, initial pulmonary artery pressures, volume replacement treatment features, blood component transfusions, corticosteroid and immunosuppressive medicines administered were recorded. While routine laboratory results were recorded for the patients one day before the operation, plasma ammonia levels were obtained through enzymatic ultraviolet- assay (Randox, VK). Complete blood count (CBS) was performed on an auto-analyzer (Siemens® Advia 2120). Serum biochemical parameters were assayed by standard kit methods using an auto-analyzer (Siemens® Advia 2400). Activated partial thromboplastin time (APTT) and International Normalized Ratio (INR) was determined by an auto-analyzer (Siemens® BCS-XP). Blood samples from patients for NSE and S100β analysis were taken during the preoperative period, in the first and sixth months of the postoperative period. Serum NSE and S100β levels were measured by enzyme-linked immunosorbent assay (ELISA) (LifeSpan BioSciences, Inc. Catalog No. LS-F5575 and Cusabio® Catalog No. CSB-E08065h, respectively). A total of 56 patients with related records have been classified under three groups according to certain criteria. Group 1, healthy donors (group D): 26 patients were recruited as healthy donors. Group 2, end-stage liver failure patients (recipient, group R): 21 recipient patients diagnosed with liver failure. Group 3 (group HE): 9 recipient patients diagnosed with liver failure along with hepatic encephalopathy. Cirrhosis diagnosis was confirmed through MELD and CTP scoring, via biopsy, laboratory findings, and imaging techniques. HE diagnosis, on the other hand, was confirmed by clinical practice and West Haven criteria grading.

本研究纳入2018至2019年间接受活体供肝原位肝移植（OLT）手术的30名供者与30名同期受者，患者年龄范围为19~65岁。本研究排除存在肿瘤性疾病、血液系统疾病、冠状动脉病变或肾衰竭、营养不良、糖尿病、颅脑创伤或接受尸体肝移植（cadaveric LT）者，以及使用精神活性药物、合并呼吸系统疾病或中枢神经系统（CNS）疾病的受试者。研究记录了患者的人口统计学资料、伴随疾病、美国麻醉医师协会（ASA）分级、主要病因、近期终末期肝病模型（MELD）评分与Child-Turcotte-Pugh（CTP）评分，以及术前常规采集的实验室检测结果；手术期间则记录了麻醉药物使用情况、手术时长、麻醉维持时间、肝前期、无肝期、新肝期、移植物热缺血与冷缺血时间、初始肺动脉压、容量复苏治疗参数、血液成分输注情况、糖皮质激素与免疫抑制药物使用情况。患者术前1天完成常规实验室检测，其中血浆氨水平采用酶紫外分析法（Randox，VK）检测；全血细胞计数（CBS）通过全自动分析仪（Siemens® Advia 2120）完成；血清生化指标采用全自动分析仪（Siemens® Advia 2400），以标准试剂盒方法检测；活化部分凝血活酶时间（APTT）与国际标准化比值（INR）则通过全自动分析仪（Siemens® BCS-XP）测定。用于神经元特异性烯醇化酶（NSE）与S100β蛋白检测的患者血样，分别于术前、术后第1个月及第6个月采集，血清NSE与S100β水平采用酶联免疫吸附试验（ELISA）分别检测（LifeSpan BioSciences, Inc. 货号LS-F5575；Cusabio® 货号CSB-E08065h）。最终共有56例拥有完整相关记录的患者，根据特定标准分为3组：第1组为健康供者组（D组），纳入26名健康供者；第2组为终末期肝衰竭受者组（R组），纳入21例确诊肝衰竭的受者；第3组为肝性脑病（HE）组，纳入9例确诊肝衰竭合并肝性脑病的受者。肝硬化诊断通过MELD与CTP评分、肝活检、实验室检测结果及影像学技术确认；肝性脑病诊断则依据临床诊疗规范与West Haven分级标准确认。

搜集汇总

背景与挑战

背景概述

该数据集是一项关于活体肝移植（OLT）的临床研究，涵盖2018年至2019年间的30名供体和30名受体，患者年龄在19至65岁之间。研究收集了广泛的多维度数据，包括人口统计学、疾病状况、手术细节、实验室结果和血液生物标志物（如NSE和S100β），并将患者分为健康供体、终末期肝衰竭和肝衰竭伴肝性脑病三组进行比较分析。这为研究肝移植相关因素（特别是肝性脑病）提供了详细的临床资料。